非小细胞肺癌PD-1免疫治疗后疗效评估与生存预测:不同评估方法的比较
结果显示所有评估方法定义的缓解者OS和PFS均显著长于未缓解者,PERCIST和imPERCIST仅分析最高代谢病灶即可准确反映整体代谢缓解。
要点
- 所有评估方法下缓解者OS和PFS均显著优于未缓解者。
- PERCIST5进展者中32%经imPERCIST5评估为疾病控制,其中22%为假性进展。
- 仅分析最高代谢病灶与分析最多5个病灶的缓解率无显著差异。
核心结论
- 所有常规和免疫治疗改良评估方法获得的缓解均与患者生存结局强相关,缓解者OS和PFS显著更长。
主要发现
- 总体缓解率和疾病控制率分别为29%和74%。
- 缓解者与未缓解者OS分别为20.3个月和10.6个月(P=0.001),PFS分别为15.5个月和2.2个月(P<0.001)。
- PERCIST1和PERCIST5缓解率分别为25%和24%(P=0.2),imPERCIST1和imPERCIST5分别为32%和29%(P=0.5)。
临床怎么用
- PERCIST和imPERCIST仅分析最高18F-FDG摄取病灶即可准确反映整体代谢缓解,可用于免疫治疗疗效监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Immunotherapy using programmed death-1 blockers is a promising modality for non-small cell lung cancer (NSCLC). Therefore, defining the most accurate response criteria for immunotherapy monitoring is of great importance in patient management. This study aimed to compare the correlation between survival outcome and response assessment by PERCIST, version 1.0; immunotherapy-modified PERCIST (imPERCIST); RECIST, version 1.1; and immunotherapy-modified RECIST (iRECIST) in NSCLC patients. Methods: Seventy-two patients with NSCLC who were treated with nivolumab or pembrolizumab and had baseline and follow-up 18F-FDG PET/CT data were analyzed. The patients were categorized into responders (complete or partial response) and nonresponders (stable or progressive disease) according to PERCIST1 and PERCIST5 (analyzing the peak SUV normalized by lean body mass [SULpeak] of 1 or up to 5 lesions), imPERCIST1, imPERCIST5, RECIST, and iRECIST. The correlation between achieved response and overall survival (OS) was compared. Results: The overall response rate and the overall disease control rate of the study population were 29% and 74%, respectively. The OS and progression-free survival (PFS) of patients with complete and partial response were statistically comparable. The OS and PFS were significantly different between responders and nonresponders (20.3 vs. 10.6 mo, P = 0.001, for OS and 15.5 vs. 2.2 mo, P < 0.001, for PFS, respectively). Twenty-three (32%) patients with progressive disease according to PERCIST5 had controlled disease according to imPERCIST5; follow-up of patients showed that 22% of these patients had pseudoprogression. The overall incidence of pseudoprogression was 7%. The response rate was 25% and 24% according to PERCIST1 and PERCIST5 (P = 0.2) and 32% and 29% according to imPERCIST1 and imPERCIST5 (P = 0.5), respectively, indicating no significant difference between analyzing the SULpeak of only the most 18F-FDG-avid lesion and analyzing up to the 5 most 18F-FDG-avid lesions. Conclusion: The achieved response by all conventional and immunotherapy-modified methods correlated strongly with patients' survival outcome, with significantly longer OS and PFS in responders than in nonresponders according to all assessed definitions. The most 18F-FDG-avid lesion according to PERCIST and imPERCIST accurately reflects the overall metabolic response.
引用
- Ayati N, Lee ST, Zakavi SR, et al. Response Evaluation and Survival Prediction After PD-1 Immunotherapy in Patients with Non-Small Cell Lung Cancer: Comparison of Assessment Methods. J Nucl Med. 2020. PMID: 33246978. doi:10.2967/jnumed.120.254508
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。